🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Atypical #EGFR mutations in #NSCLC may benefit most from a typical treatment: osimertinib. Our retrospective analysis presented at #ASCO2024 now published in Lung Cancer Journal Melina Marmarelis Penn Medicine - Abramson Cancer Center University of Penn IM Residency Program kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2…

Thanks for our resident Adam Barsouk MD hard work and dedication. Appreciate Ronac Mamtani support for your review article. We have found women's bladder cancer still has inferior outcomes even in the modern treatment era.

New publication alert:🚨Osimertinib demonstrated superior PFS and OS and improved tolerability compared to afatinib or erlotinib for atypical EGFR-mutated metastatic non–small cell #LungCancer. Adam Barsouk MD Corey Langer Lung Cancer Journal #NSCLC spr.ly/6010UktC0

We found that across the US, bladder cancer trials include <2% Black patients and women still have poorer survival— we must do better! Lin Mei Penn Medicine - Abramson Cancer Center mdpi.com/2977898

Seems more immunotherapy side effects = improved survival in head and neck cancer— is this a silver lining for patients, or predictable/preventable collateral damage? Penn Medicine - Abramson Cancer Center University of Penn IM Residency Program tandfonline.com/doi/full/10.10…

Approach to HLH Ref: PMID: 30992265, DOI: 10.7759/cureus.22411, eClinicalMedicine 2023;62: 102143, DOI 10.3389/fimmu.2023.1210041

🫁 Osimertinib showed improved PFS, OS & tolerability compared to afatinib or erlotinib in atypical EGFR-mutated mNSCLC, according to a real-world analysis published in Lung Cancer Journal by Adam Barsouk MD of Penn Medicine - Abramson Cancer Center & colleagues. ➡️ Read more: buff.ly/3z33LiD #lcsm #NSCLC

"As a doc­tor in Phil­a­del­phia, I had a sink­ing feel­ing which way the elec­tion was headed. Now many of my pa­tients will have to grap­ple with the con­se­quences of the choice they made." Pittsburgh Post-Gazette #ElectionDay #HealthcareForAll post-gazette.com/opinion/guest-…

Doctors should lead the Dept of Health. Not vaccine-skeptics and charlatans like RFK Jr. Facts. #PublicHealth #vaccineswork

For MET-alt osi refractory #NSCLC, our #realworld study found #Capmatinib + osi produced a durable response (mPFS ~18m). Big advance for #targeted therapy! Thank you Clinical Lung Cancer Melina Marmarelis Charu Aggarwal, MD, MPH, FASCO Lova Sun sciencedirect.com/science/articl…

Omar Elghawy et al. describe outcomes, including new information on survival & toxicity, with #cabozantinib in a real-world cohort of poorly differentiated #thyroid #carcinomas, many of whom had progressed on prior multi-kinase inhibitors. Read it here 👉 doi.org/10.1530/ETJ-24…

We share ASCO GU our findings on race/sex #disparity in #bladdercancer: women get inferior PFS on #immunotherapy, while Asians/Pacific Islanders see superior PFS/OS Lin Mei omar elghawy meetings.asco.org/abstracts-pres…

WHAT A WONDERFUL DISCUSSION! Discussing NUT Carcinoma and Mesothelioma with these amazing ladies Dr. Melina Marmarelis and Jia Luo, MD at #TTLC25 IASLC

#TTLC25 IASLC Best oral presentations with amazing presentations by trainees & junior faculty : Kelsey Pan, MD, MPH MD Anderson Cancer Center Federica Pecci Dana-Farber News Adam Barsouk MD Abramson Cancer Ctr @lingfenye Memorial Sloan Kettering Cancer Center Divyagupta Northwestern Feinberg School of Medicine #lcsm

Thank you Melina Marmarelis Corey Langer Charu Aggarwal, MD, MPH, FASCO IASLC University of Penn IM Residency Program for making this research possible! #LungCancer patients deserve #PrecisionOncology

Real world analysis of osimertinib vs afatinib in atypical #EGFR NSCLC Lung Cancer Journal. Outcomes varied by specific mutation: for G719X, afatinib had better outcomes (time to discontinuation 20.3m vs 9.4m) but for L861Q, osimertinib had an advantage. lungcancerjournal.info/article/S0169-…

Our new real-world analysis found patients with different atypical #EGFR mutations live longer with different therapies: G719X=afatinib; L861Q= osimertinib #lungcancer #precisiononc Lung Cancer Journal Penn Medicine - Abramson Cancer Center Melina Marmarelis Charu Aggarwal, MD, MPH, FASCO Corey Langer lungcancerjournal.info/article/S0169-…

We found #Immunotherapy for >2 years in #NSCLC resulted in more late adverse events. Should oncs stop at 2y? Penn Medicine - Abramson Cancer Center omar elghawy Melina Marmarelis Lova Sun sciencedirect.com/science/articl…

Fantastic representation of #Thoracic oncology ASCO #ASCO25 posters! Ben Bleiberg Melina Marmarelis Corey Langer Lova Sun Penn Medicine - Abramson Cancer Center Penn Medicine MD Penn Medicine

Charu Aggarwal, MD, MPH, FASCO ASCO Ben Bleiberg Corey Langer Lova Sun Penn Medicine - Abramson Cancer Center Penn Medicine MD Penn Medicine Love seeing @penncancer in action with Adam Barsouk MD, matching coats with #LaurenReedGuy and discussions with Corey Langer and Ben Bleiberg !! So proud of these researchers!!! -you too Corey 😂